White, D., LeBlanc, R., Venner, C., Bahlis, N. J., Lentzsch, S., Gasparetto, C. J., … Schiller, G. J. (2019). Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). In Clinical Lymphoma Myeloma and Leukemia (Vol. 19, pp. e55–e55). Elsevier BV. https://doi.org/10.1016/j.clml.2019.09.084

White, Darrell, Richard LeBlanc, Chritopher Venner, Nizar J. Bahlis, Suzanne Lentzsch, Cristina J. Gasparetto, Christine Chen, et al. “Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM).” In Clinical Lymphoma Myeloma and Leukemia, 19:e55–e55. Elsevier BV, 2019. https://doi.org/10.1016/j.clml.2019.09.084.

White D, LeBlanc R, Venner C, Bahlis NJ, Lentzsch S, Gasparetto CJ, et al. Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). In: Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2019. p. e55–e55.

White, Darrell, et al. “Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM).” Clinical Lymphoma Myeloma and Leukemia, vol. 19, no. 10, Elsevier BV, 2019, pp. e55–e55. Crossref, doi:10.1016/j.clml.2019.09.084.

White D, LeBlanc R, Venner C, Bahlis NJ, Lentzsch S, Gasparetto CJ, Chen C, Lipe B, Sutherland H, Tuchman S, Baljevic M, Kotb R, Sebag M, Callander N, Bensinger W, Kai K, Liu J, Sheehan H, Estepan DN, Shah J, Schiller GJ. Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma and Leukemia. Elsevier BV; 2019. p. e55–e55.